SCHEMBL9989950

SCHEMBL9989950

O=C(Cc1ccnc(Cl)n1)c1cccc(NS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HDAC2 Q92769 3/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
PFKFB3 Q16875 1/20 0.46
POLB P06746 1/20 0.46
ITGA1 P56199 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
EGFR P00533 2/20 0.44
FGFR1 P11362 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9988807 0.85 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2HDAC2HDAC8HDAC6
SCHEMBL3422489 0.82 NPC1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL12040624 0.80 TCF4 (0.49) ALDH1A1SMN1; SMN2HDAC2HDAC8HDAC6
SCHEMBL24760727 0.79 RAB9A (0.53) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL4606413 0.76 HDAC2 (0.60) HDAC2HDAC8HDAC6HDAC3HDAC4
SCHEMBL24760920 0.76 ERCC5 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1640536 0.74 KCNQ3 (0.45) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL13905926 0.74 ACHE (0.40) ALDH1A1SMN1; SMN2
SCHEMBL27840643 0.74 HDAC2 (0.60) ALDH1A1HDAC2HDAC8HDAC6HDAC3
SCHEMBL310067 0.74 RAB9A (0.44) SMN1; SMN2POLBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-12-29 US disclosed
WO-2010104899-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319392-A1 Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors STK24, MAP3K5, MAP3K2 ALDH1A1 2613/4885SMN1; SMN2 2927/4885HDAC2 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.